Skip to main content
Premium Trial:

Request an Annual Quote

Illumina Places Genetic Analyzer at Undisclosed Top-5 Pharma

NEW YORK (GenomeWeb News) — Illumina today said that an undisclosed top-5 US pharma company has bought a “multi-component genetic analysis system” and will use Illumina's Infinium assay and HumanHap650Y BeadChip to provide whole-genome genotyping in a project involving over 3,200 samples.
 
This configuration will enable the pharma to generate as many as 45 million genotypes per day and run gene-expression applications and automated sample and array processing, Illumina said.
 
Though the drug maker was undisclosed, a person close to the deal suggested it is likely either GlaxoSmithKline or Merck. Both companies have had recent relationships with San Diego-based Illumina, as reported by GenomeWeb News sister publication BioArray News.
 
Financial terms of the deal were not disclosed, though Illumina said this is a multi-million dollar deal. The company said it will issue details, including the name of the company, during its third-quarter conference call later today.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.